Navigation Links
GCpro Taq DNA Polymerase Complete System from GenScript Corporation

ProductsGCpro Taq DNA Polymerase Complete System from GenScript Corporation
Company GenScript Corporation
Item GCpro Taq DNA Polymerase Complete System
Price $125.00
Description GCpro Taq DNA Polymerase is a versatile and easy-to use enzyme, with powerful advantages for all PCR applications. GCpro Taq DNA Polymerase is prepared from a recombinant clone expressed in E. coli, containing the DNA polymerase I gene from Thermococcus litoralis. The enzyme includes a highly processive 5'-3' DNA polymerase activity. Its inherent 3'-5' proofreading activity results in a greatly increased fidelity of DNA synthesis compared to Taq DNA Polymerase. The enzyme includes an optimized reaction buffer, which enables the amplification of GC-rich templates and problematic templates with secondary structures that interfere with the PCR process. GCpro Taq DNA Polymerase provides a very robust synthesis of longer GC-rich amplification products. GCpro Taq DNA Polymerase has all the properties of regular Taq DNA Polymerases for every standard PCR application. It is versatile, user-friendly and compatible with all PCR applications such as GC-rich and other complex templates, site-directed mutagenesis as well as TA cloning due to its extendase activity.
Info GenScript CorporationGenScript Corporation
120 Centennial Ave.
Piscataway, NJ 08854

Customer Service: (Toll Free) : (877) 436-7274
(732) 885-9188
(732) 885-9688
Fax Number: (732) 210-0262
(732) 885-587
Web Site:
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. T4 DNA Polymerase from Roche Applied Science
2. T4 DNA Polymerase from Roche Applied Science
3. Poly A Polymerase from Invitrogen
4. iTaq DNA Polymerase, 250 U from Bio-Rad
5. iTaq DNA Polymerase, 5,000 U from Bio-Rad
6. Taq DNA Polymerase, 500 U (2 x 250 U) without dNTP from Bioneer, Inc.
7. T4 DNA Polymerase from Invitrogen
8. T4 DNA Polymerase from New England Biolabs
9. SP6 RNA Polymerase from Roche Applied Science
10. Taq DNA Polymerase (cloned) from GE Healthcare, formerly Amersham Biosciences
11. Mango-Taq DNA Polymerase from Bioline
... in Dec 2005 , Quantitative results ... Detection from as little as 25 pg of ... for hundreds of mammalian miRNAs , ... , Ideal for validating expression profiling data ...
jub, ajuba homolog (Xenopus laevis)...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Prepared in distilled water....
Biology Products:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology: